Nanox to Report Third Quarter 2021 Results on November 17, 2021

Rhea-AI Summary

NANO-X IMAGING LTD (NNOX) is set to report its third-quarter results for the period ending September 30, 2021, on November 17, 2021, before market opening. Ran Poliakine, the CEO, along with Erez Meltzer, the newly appointed CEO effective January 1, 2022, will lead a conference call at 8:30 a.m. ET to discuss the results and provide a business update. Interested parties can join via phone or webcast. Nanox aims to transform medical imaging with its innovative digital X-ray technology.

NEVE ILAN, Israel--(BUSINESS WIRE)-- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX) will report its results for the third quarter ended September 30, 2021 before market on Wednesday, November 17, 2021. Ran Poliakine, Chairman and Chief Executive Officer, and Erez Meltzer, Director (appointed CEO effective January 1, 2022), will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.

Interested parties may access the conference call by dialing (877) 550-3765 (Domestic) or (409) 937-8962 (International) and reference Access Code 7872065. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Nanox website at Investors | Nano-X Imaging LTD. (nanox.vision)

About Nanox

Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli corporation developing a commercial-grade digital X-ray source designed to be used in real-world medical imaging applications. Nanox believes that its novel technology could significantly reduce the costs of medical imaging systems and plans to seek collaborations with world-leading healthcare organizations and companies to provide affordable, early detection imaging services for all. For more information, please visit www.nanox.vision.

Forward-Looking Statements

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of Nanox's research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.ARC. In some cases, you can identify forward-looking statements by terminology such as "can," "might," "believe," “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information Nanox has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to Nanox's ability to complete development of the Nanox.ARC; Nanox's ability to successfully demonstrate the feasibility of its technology for commercial applications; Nanox's expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its X-ray source technology and the Nanox.ARC from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; Nanox's ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; the market acceptance of the Nanox.ARC and the proposed pay-per-scan business model; Nanox's expectations regarding collaborations with third-parties and their potential benefits; Nanox's ability to conduct business globally; and risks and business interruptions related to the COVID-19 pandemic, among others. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox's actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2020 and subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Nanox's expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005551/en/

Mike Cavanaugh

Westwicke ICR

Mike.Cavanaugh@westwicke.com

Tamar Aharon Cohen

Nanox Imaging

IR@nanox.vision

Source: NANO-X IMAGING LTD

FAQ

When will Nano-X Imaging report its Q3 2021 results?

Nano-X Imaging will report its Q3 2021 results on November 17, 2021.

What time is the conference call for Nano-X Imaging's Q3 results?

The conference call for Nano-X Imaging's Q3 results will be held at 8:30 a.m. ET.

Who will present the Q3 results for Nano-X Imaging?

Ran Poliakine, the CEO, and Erez Meltzer, the new CEO effective January 1, 2022, will present the Q3 results.

How can I access the Q3 conference call for Nano-X Imaging?

You can access the Q3 conference call by dialing (877) 550-3765 for domestic or (409) 937-8962 for international calls, using access code 7872065.

What is the ticker symbol for Nano-X Imaging?

The ticker symbol for Nano-X Imaging is NNOX.